Andrew John Armstrong, MD

Professor of Medicine
Professor in Surgery
Professor in Pharmacology and Cancer Biology
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

In Their Words

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania, School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996



Patierno, Brendon M., Wen-Chi Foo, Tyler Allen, Jason A. Somarelli, Kathryn E. Ware, Santosh Gupta, Sandra Wise, et al. “Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.” In Prostate Cancer Prostatic Dis, 2021.

Full Text

Penson, David F., Andrew J. Armstrong, Raoul S. Concepcion, Neeraj Agarwal, Carl A. Olsson, Lawrence I. Karsh, Curtis J. Dunshee, et al. “Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.” Prostate Cancer Prostatic Dis, October 7, 2021.

Full Text

Tombal, Bertrand F., Stephen J. Freedland, Andrew J. Armstrong, Tomasz M. Beer, Arnulf Stenzl, Cora N. Sternberg, Maha Hussain, et al. “Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials.” Prostate Cancer Prostatic Dis, September 13, 2021.

Full Text

Sperger, Jamie M., Hamid Emamekhoo, Rana R. McKay, Charlotte N. Stahlfeld, Anupama Singh, Xinyi E. Chen, Lucia Kwak, et al. “Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.” J Clin Oncol 39, no. 26 (September 10, 2021): 2926–37.

Full Text

Armstrong, Andrew J., Xiaotong Li, Matthew Tucker, Shantao Li, Xinmeng Jasmine Mu, Kenneth Wha Eng, Andrea Sboner, Mark Rubin, and Mark Gerstein. “Molecular medicine tumor board: whole-genome sequencing to inform on personalized medicine for a man with advanced prostate cancer.” Prostate Cancer Prostatic Dis 24, no. 3 (September 2021): 786–93.

Full Text

Fong, Lawrence, Michael J. Morris, Oliver Sartor, Celestia S. Higano, Lance Pagliaro, Ajjai Alva, Leonard J. Appleman, et al. “A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27, no. 17 (September 2021): 4746–56.

Full Text

Azad, Arun A., Andrew J. Armstrong, Antonio Alcaraz, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, et al. “Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.” Prostate Cancer Prostatic Dis, August 21, 2021.

Full Text

George, Daniel J., Susan Halabi, Elisabeth I. Heath, A Oliver Sartor, Guru P. Sonpavde, Devika Das, Rhonda L. Bitting, et al. “A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.” Cancer 127, no. 16 (August 15, 2021): 2954–65.

Full Text

Koshkin, Vadim S., Vaibhav G. Patel, Alicia Ali, Mehmet A. Bilen, Deepak Ravindranathan, Joseph J. Park, Olesia Kellezi, et al. “PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.” Prostate Cancer Prostatic Dis, August 6, 2021.

Full Text

Morris, Michael J., Jose Mauricio Mota, Kristine Lacuna, Patrick Hilden, Martin Gleave, Michael A. Carducci, Fred Saad, et al. “Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).” Eur Urol Oncol 4, no. 4 (August 2021): 543–52.

Full Text